| Metric | Value | Detail |
|---|---|---|
| Revenue | $12.0B | +8.9% YoY |
| Net income | $4.0B | 32.9% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | 34.8% | Operating income / revenue |
| Return on equity | 21% | Net income / equity |
| Return on assets | 15% | Net income / assets |
| Revenue growth (YoY) | +8.9% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +10.4% | Compound annual |
| Diluted EPS | $15.46 | FY2025 |
| Debt-to-equity | n/a | Long-term debt / equity |
| Current ratio | 2.90 | Current assets / liabilities |
| Cash & equivalents | $5.1B | Balance sheet |
| Total assets | $25.6B | FY2025 year-end |
| Shareholders’ equity | $18.7B | FY2025 year-end |
| Share price | $485.39 | Delayed · 2026-07-10 |
| Market cap | $123.2B | Price × shares outstanding |
| P/E ratio | 31.2 | Market cap / net income |
| P/S ratio | 10.3 | Market cap / revenue |
| Dividend yield | n/a | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
VERTEX PHARMACEUTICALS INC / MA (VRTX) stock fundamentals
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported $12.0B in revenue and $4.0B in net income in fiscal 2025, a 32.9% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $123.2B at a delayed share price. It scores 65/100 on WealthyBud's Investor Score, ranking #19 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$12.0B
▲ +8.9% YoY
Net income
$4.0B
32.9% net margin
Market cap
$123.2B
Price $485.39 · delayed
P/E ratio
31.2
Price / earnings
Return on equity
21%
Net income / equity
Investor Score
65/100
#19 of 100 covered
VERTEX PHARMACEUTICALS INC / MA fundamentals at a glance
The table summarizes VERTEX PHARMACEUTICALS INC / MA's key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is VERTEX PHARMACEUTICALS INC / MA?
VERTEX PHARMACEUTICALS INC / MA runs a 32.9% net margin and n/a gross margin in fiscal 2025, turning $12.0B of revenue into $4.0B of profit. Return on equity is 21% and return on assets 15%.
Is VERTEX PHARMACEUTICALS INC / MA growing?
VERTEX PHARMACEUTICALS INC / MA's revenue changed +8.9% in fiscal 2025 and compounded at +10.4% a year over three years, reaching $12.0B. Diluted earnings per share were $15.46 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $7.6B | n/a |
| 2022 | $8.9B | +17.9% |
| 2023 | $9.9B | +10.5% |
| 2024 | $11.0B | +11.7% |
| 2025 | $12.0B | +8.9% |
How is VERTEX PHARMACEUTICALS INC / MA valued?
VERTEX PHARMACEUTICALS INC / MA carries a market capitalization of $123.2B at a delayed share price of $485.39, trading at a 31.2 price-to-earnings ratio and 10.3 price-to-sales. Its Value subscore is 30/100 across the covered universe.
How financially healthy is VERTEX PHARMACEUTICALS INC / MA?
VERTEX PHARMACEUTICALS INC / MA ended fiscal 2025 with $5.1B in cash, a debt-to-equity ratio of n/a and a current ratio of 2.90. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is VERTEX PHARMACEUTICALS INC / MA's Investor Score?
VERTEX PHARMACEUTICALS INC / MA scores 65/100 on WealthyBud's Investor Score, #19 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
65/100
#19 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
VERTEX PHARMACEUTICALS INC / MA (VRTX) stock FAQ
How much revenue does VERTEX PHARMACEUTICALS INC / MA make?
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported $12.0B in revenue in fiscal 2025, +8.9% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +10.4% a year.
Is VERTEX PHARMACEUTICALS INC / MA profitable?
Yes. VERTEX PHARMACEUTICALS INC / MA earned $4.0B in net income in fiscal 2025, a 32.9% net margin. Its return on equity was 21% and return on assets 15%, based on figures from its latest 10-K.
How fast is VERTEX PHARMACEUTICALS INC / MA growing?
VERTEX PHARMACEUTICALS INC / MA's revenue changed +8.9% year over year in fiscal 2025 and compounded at +10.4% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 44/100 versus the covered universe.
What is VERTEX PHARMACEUTICALS INC / MA's market cap and P/E ratio?
VERTEX PHARMACEUTICALS INC / MA has a market capitalization of $123.2B at a delayed share price of $485.39, trading at a price-to-earnings ratio of 31.2 and price-to-sales of 10.3. Its dividend yield is n/a. Prices are delayed and illustrative.
What is VERTEX PHARMACEUTICALS INC / MA's WealthyBud Investor Score?
VERTEX PHARMACEUTICALS INC / MA scores 65/100, ranking #19 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (44), profitability (88), returns on capital (68), balance-sheet strength (94) and value (30). It is a research opinion, not investment advice.
Where does this VERTEX PHARMACEUTICALS INC / MA financial data come from?
Fundamentals come from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from VERTEX PHARMACEUTICALS INC / MA’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.